Thomas J. Lanza
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Cell Adhesion Molecules Research, Peptidase Inhibition and Analysis, Cannabis and Cannabinoid Research, Chemical Synthesis and Analysis, Neuropeptides and Animal Physiology
Most-Cited Works
- → Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity(2006)122 cited
- → Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents(2007)101 cited
- → Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding(1992)85 cited
- → Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques(2003)77 cited
- → Inhibition of Stromelysin-1 (MMP-3) by P1‘-Biphenylylethyl Carboxyalkyl Dipeptides(1997)66 cited
- → 2-(Substituted phenyl)oxazolo[4,5-b]pyridines and 2-(substituted phenyl)oxazolo[5,4-b]pyridines as nonacidic antiinflammatory agents(1978)65 cited
- → Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides(1993)64 cited
- → Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity(2012)62 cited
- → The discovery of sulfonylated dipeptides as Potent VLA-4 antagonists(2001)59 cited
- → 6-substituted indoles from o-halonitrobenzenes(1986)50 cited